FDA Releases Draft Guidance on User Fees and Marketing Applications

Summary

The FDA has released a draft guidance on how to separate marketing applications and define clinical data for assessing user fees, revising a 1993 interim guidance and directing readers to the Orange Book for routes of administration and dosage forms.